Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/tazobactam versus meropenem in ventilated nosocomial pneumonia
2012-002862-11Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) comparing Ceftolozane/tazobactam with Meropenem (2 arms). Primary endpoints: Clinical response at the TOC visit in the ITT population and Non-inferiority of ceftolozane/tazobactam versus meropenem. Started Jul 2014; status: completed.
02
Drugs
ceftolozane + tazobactammeropenem
03
Conditions
ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2012-002862-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002862-11.